Study identifier:D0850C00014
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A phase 1, single centre, single dose, double-blind, double-dummy, four-way crossover, placebo-controlled, randomized study to investigate the effects of AZD6280 on sedation, cognition and EEG in comparison with lorazepam in healthy male volunteers
Healthy Volunteer
Phase 1
Yes
AZD6280, Lorazepam, Placebo
Male
17
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of the study is to determine the effects of AZD6280 compared to lorazepam on sleepiness, concentration and brain activity.
Location
Location
Leiden, Netherlands
Arms | Assigned Interventions |
---|---|
Experimental: 1 | Drug: AZD6280 10mg Capsule, oral, single-dose |
Experimental: 2 | Drug: AZD6280 40mg Capsule, oral, single-dose |
Active Comparator: 3 | Drug: Lorazepam 2mg tablet, oral single-dose Other Name: Ativan |
Placebo Comparator: 4 | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.